@article{article, title  = {{Laboratory safety from a randomized 16-week phase III study of dupilumab in children aged 6 months to 5 years with moderate-to-severe atopic dermatitis}},

 publisher = {{Springer Science and Business Media LLC}},

 url = {{}},

 year = {{2022}},

 month = {{12}},

 author = {{Paller AS and Siegfried EC and Cork MJ and Wollenberg A and Arkwright PD and Gonzalez ME and Lockshin B and Chen Z and Bansal A and Levit NA and Prescilla R}},

 doi = {{10.1007/s40272-022-00553-8}},

 volume = {{25}},

 journal = {{Pediatric Drugs}},

 pages = {{67-77}},

 note = {{Accessed on 2024/12/22}}}